Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer taps Roche for new CEO

by Alex Scott
February 24, 2023 | A version of this story appeared in Volume 101, Issue 7

 

Bill Anderson, who will become CEO of Bayer on June 1.
Credit: Bayer
Bill Anderson

Bayer has appointed Bill Anderson, a senior executive with Roche and former CEO of Genentech, its chief executive effective June 1. Anderson replaces Werner Baumann, whose term had been due to run until April 2024. Baumann has had a torrid few years as CEO. His 2018 acquisition of Monsanto exposed Bayer to thousands of lawsuits claiming that its leading product, Roundup, causes cancer. In addition, Bayer’s drug development pipeline has underwhelmed some investors.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.